Twist Bioscience Corp. Stock News

SOUTH SAN FRANCISCO, Calif. & SAN DIEGO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, and Element Biosciences, Inc., a company democratizing access to advanced life science solutions, today announced the launch of Twist's new Trinity Freestyle Fast Hybridization workflow for Element's AVITI™ sequencing platforms, a user-friendly, end-...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced the publication in Science of the peer-reviewed paper, “Strengthening nucleic acid biosecurity screening against generative protein design tools,” led by Microsoft and co-authored with a consortium of scientific and industry experts including the...

NEW YORK , Sept. 15, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ: TWST)  breached their fiduciary duties to shareholders.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the Baird 2025 Global Healthcare Conference on Tuesday, September 9, 2025 at 9:40 am Eastern Time in New York City. The company will also host one-on-one meeti...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has collaborated with next generation therapeutics company, Synthetic Design Lab (SDL). “With our high throughput expertise, from novel binder discovery services to high throughput screening capabilities, we're able to support researchers...

mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery challenges and limited efficacy for cancer and infectious diseases, make mRNA-focused biotechs unattractive compared to broader biotech opportunities. Investors seeking exposure should consider 'pic...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity, in the life sciences segment of the health care sector, today launched the Twist Oncology DNA Comprehensive Genomic Profiling (CGP) Panel, a customizable, research-use-only solution designed to empower users to identify genomic alterations for a broad set of tumors,...

Twist Bioscience's growth continues to moderate, in part due to macro headwinds. While Twist's focus on transitioning to profitability in the near-term has significantly reduced cash burn, it has also taken much of the upside off the table. Twist's NGS business continues to be a growth driver, but much of this is already reflected in the share price.